INR measurements generated by POC devices exhibited positive bias, compared with laboratory-based venipuncture, for INR values at the high end of the INR range.
BackgroundVitamin K antagonists have been the treatment of choice in preventing
thromboembolic events, but problems such as frequent dose adjustment and
monitoring of coagulation status, including multiple drug and food
interactions, make their use difficult. Dabigatran etexilate is a new oral
direct thrombin inhibitor not requiring routine monitoring and since its
approval in the United States, many clinicians have been interested in
utilizing this new therapy.ObjectiveThis study documented adverse drug events (ADEs) recorded in patients started
on dabigatran therapy, including those who were previously controlled on
warfarin and those who were anticoagulant naïve.MethodsIn an outpatient pharmacist-managed anticoagulation clinic, a total of 221
patients were initiated on dabigatran therapy over an 18-month period. 43.0%
of these patients were previously controlled on warfarin.Results54 of the 221 patients (24.4%) developed an ADE while on dabigatran. The
average time to event was 48.4 days. Nine of the fifty-four patients
experienced a major bleeding ADE; six patients developed a serious
non-bleeding ADE. Five of these fifteen patients died; one death was
directly related to dabigatran therapy. The remaining thirty-nine of the
fifty-four patients experienced a clinically relevant non-major ADE. Of the
fifty-four patients who experienced an ADE, thirty were male. The average
age was 73.8 years and the average weight was 92.8kg. Fifty-four percent of
those who experienced an ADE were previously anticoagulant naïve.ConclusionsWhile many clinicians have been interested in utilizing the new direct
thrombin inhibitor dabigatran etexilate, this new therapy is not without
risks. This study documented adverse drug events in 24.4% of patients who
were initiated on dabigatran etexilate therapy over an eighteen month
period. ADEs were more common in patients who were anticoagulant naïve prior
to dabigatran etexilate therapy and not those who were previously controlled
on warfarin therapy.
as opposed to the aforementioned factor of 1.86. If the new dosage of 110 mg twice daily were used for CL cr values of 30-50 mL/min, the average C ss values would be similar: 0.231, 0.236, and 0.235 mg/mL for CL cr values of >50, 30-50, and <30 mL/min, respectively. Dosages appearing in dabigatran product labeling may not be optimal for patients with a CL cr of 30-50 mL/min. For this group, a dabigatran etexilate dosage of 110 mg orally twice daily may produce a better balance of safety and effectiveness. A 110-mg dosage form of dabigatran etexilate is available in Canada but not in the Unit-5. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51. 6. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor.ed States, but a 150-mg capsule could be taken in the morning and a 75-mg capsule at night.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.